

Worldwide Clinical and Real-World Exposure to Baricitinib

Ruth Ann Vleugels¹, Brittany Craiglow², Arash Mostaghimi¹, Elise Olsen³, Angelina Sontag⁴, Karen Denning⁴, Najwa Somani⁴, Maria Hordinsky⁵

¹Brigham and Women’s Hospital, Boston, USA, ²Yale School of Medicine, New Haven, USA, ³Duke Dermatology Clinic, Durham, USA, ⁴Eli Lilly and Company, Indianapolis, USA, ⁵University of Minnesota, Minneapolis, USA

Sponsored by Eli Lilly and Company under license from Incyte Corporation

OBJECTIVE

- To report the worldwide real-world and clinical trial exposure to baricitinib across a range of diseases, ages, and racial backgrounds

CONCLUSIONS

- Over 14,600 patients have received baricitinib in clinical trials and an estimated >1.8 million patients have received baricitinib in the real-world setting
 - As the average daily dose and length of therapy may vary over time, real-world exposures are only an estimate of the total number of patients receiving baricitinib
- Baricitinib use in 59 completed and ongoing clinical trials spans a variety of populations and disease states
 - 4870 patients with dermatologic conditions
 - 2941 patients who were Asian or Black
 - 866 patients aged <1 month to <18 years (including an ongoing AD study¹, but not an ongoing AA study²)
- The exposure data in this analysis provide a view of the ages, indications, and racial populations in which baricitinib has been studied over time in clinical trials. It also provides a view of the populations in which baricitinib has been used in the real-world setting

Winter Clinical Dermatology Conference – Miami; Miami, FL, USA; January 17 - 20, 2025



BACKGROUND

- Baricitinib, an oral selective JAK inhibitor, is approved in many geographies for adults with rheumatoid arthritis or alopecia areata, and for patients as young as 2 years of age with atopic dermatitis or juvenile idiopathic arthritis
- Baricitinib is also approved in the United States for hospitalized patients with COVID-19 infection

ANALYSIS SETS



Real-World Exposure^a

- Latest data cut-off to January 31, 2024
- Estimates based on:
 - Total mg sold
 - Average daily dose
 - Average length of therapy

Clinical Trial Exposure


- Latest data cut-off to February 13, 2024
- Includes data for both ongoing and completed trials

^aEstimates were calculated based on total milligrams sold, average daily dose, and average length of therapy as reported to regulatory agencies through the cumulative timeframe ending January 31, 2024.



Reference: 1. Wollenberg A, et al. Poster presented at: EADV 2023. Poster P0499. 2. <https://clinicaltrials.gov/search?term=NCT05723198>. Accessed September 2024

Abbreviations: AA=alopecia areata; AD=atopic dermatitis; BARI=baricitinib; COVID-19=coronavirus 2019; JAK=Janus kinase; JIA=juvenile idiopathic arthritis; RA=rheumatoid arthritis



^aIncludes patients with rare autoimmune syndromes expected to benefit from JAK inhibition (compassionate-use treatment program) (n=71) and patients with biliary cholangitis (n=1), renal impairment (n=36), diabetic kidney disease (n=103), hepatic dysfunction (n=8), and autoimmune type I interferonopathies (n=10); ^bIncludes plaque psoriasis (n=256), atopic dermatitis (n=3050), and alopecia areata (n=1564); ^cIncludes rheumatoid arthritis (n=6242), systemic lupus erythematosus (n=1662), and juvenile idiopathic arthritis (n=291).

Disclosures: R. Vleugels is a consultant for: AbbVie, AstraZeneca, Eli Lilly and Company, and Proviant Therapeutics; B. Craiglow has received fees and/or honoraria from: AbbVie, Arcutis, BiologicsMD, Dermavant, Eli Lilly and Company, GlaxoSmithKline, Incyte Corporation, LEO Pharma, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma; A. Mostaghimi has been a consultant for: AbbVie, Concert Pharmaceuticals, Digital Diagnostics, Eli Lilly and Company, and Pfizer; E. Olsen has been an advisory board member for: Eli Lilly and Company; and has been a consultant for: Kintor Pharmaceutical, Pfizer, and Taisho Pharmaceutical; A. Sontag, K. Denning, and N. Somani are employees and shareholders of: Eli Lilly and Company; M. Hordinsky has received grants from: AnaptysBio, Arcutis, ASLAN Pharmaceuticals, Concert Pharmaceuticals, Eli Lilly and Company, National Alopecia Areata Foundation, Pfizer, RegenLab, and Technoderm Medines; has received honoraria and has been consultant/advisory board member for: AbbVie, Almirall, Eli Lilly and Company; and has been an *UpToDate* Section Editor on: Hair Medical writing assistance was provided by Serina Stretton, PhD, CMPP, of ProScribe – Envision Pharma Group, and was funded by Eli Lilly and Company Previously presented at Fall Clinical 2024; Las Vegas, USA; 24-27 October 2024

